Uterine Sarcoma: The Indian Scenario
- PMID: 27217670
- PMCID: PMC4856672
- DOI: 10.1007/s13193-015-0433-9
Uterine Sarcoma: The Indian Scenario
Abstract
Uterine sarcomas are rare, highly malignant tumours comprising < 1 % of all gynaecologic malignancies. To evaluate clinical presentation, histolopathologic pattern and outcome of uterine sarcomas presenting to a tertiary referral centre over an 8 year period (2004-2012). All histologically proven uterine sarcomas were retrospectively analysed. Clinical presentation, histology, treatment and outcome were analysed. Mean age was 42 years. Predominant histopathology was endometrial stromal sarcoma (n = 13); 9 were low grade, carcinosarcoma (n = 8) and leiomyosarcoma (n = 2). Fourteen patients had Stage I disease, 3 Stage II, 4 Stage III and 2 were Stage IV at presentation. Patients with disease confined to uterus received no adjuvant treatment (61 %). Of these, 11 were endometrial stromal sarcoma (7 were low grade) and 3 were carcinosarcomas. Four patients received adjuvant EBRT following hysterectomy (17 %). Two patients who presented with metastases received palliative chemotherapy. Mean follow-up period was 46 months (0-86 months). Eleven patients (47 %) developed disease recurrence. Seven (30 %) had local recurrence, while 4 (17 %) developed pulmonary metastases. A total of eight patients died and all deaths were within 1 year of recurrence. The only prognostic factor that correlated with survival was the stage of disease at diagnosis.
Keywords: Carcinosarcoma; Endometrial stromal sarcoma; Gynaecologic cancers; Gynaecologic sarcoma; Leiomyosarcoma; Uterine sarcoma.
Similar articles
-
Uterine Sarcomas: Experience from a Tertiary Cancer Care Center from India.Indian J Surg Oncol. 2019 Jun;10(2):342-349. doi: 10.1007/s13193-018-0860-5. Epub 2019 Jan 5. Indian J Surg Oncol. 2019. PMID: 31168260 Free PMC article.
-
Uterine sarcoma-current management and experience from a regional cancer centre in North India.Arch Gynecol Obstet. 2013 Oct;288(4):873-82. doi: 10.1007/s00404-013-2843-7. Epub 2013 Apr 12. Arch Gynecol Obstet. 2013. PMID: 23580012
-
[Uterine sarcomas: clinical and histopathological aspects. Report on 15 cases].Gynecol Obstet Fertil. 2008 Jun;36(6):628-35. doi: 10.1016/j.gyobfe.2008.03.012. Epub 2008 Jun 5. Gynecol Obstet Fertil. 2008. PMID: 18538624 French.
-
The management of patients with uterine sarcoma: a debated clinical challenge.Crit Rev Oncol Hematol. 2008 Feb;65(2):129-42. doi: 10.1016/j.critrevonc.2007.06.011. Epub 2007 Aug 13. Crit Rev Oncol Hematol. 2008. PMID: 17706430 Review.
-
Role of radiotherapy treatment of uterine sarcoma.Best Pract Res Clin Obstet Gynaecol. 2011 Dec;25(6):761-72. doi: 10.1016/j.bpobgyn.2011.06.004. Epub 2011 Jul 23. Best Pract Res Clin Obstet Gynaecol. 2011. PMID: 21783424 Review.
Cited by
-
Immunohistochemical and Molecular Characterization of Endometrial Stromal Sarcomas.Clin Pathol. 2020 May 11;13:2632010X20916736. doi: 10.1177/2632010X20916736. eCollection 2020 Jan-Dec. Clin Pathol. 2020. PMID: 32524088 Free PMC article.
-
Giant Uterine Tumor Compatible With Sarcoma.Cureus. 2025 Mar 5;17(3):e80101. doi: 10.7759/cureus.80101. eCollection 2025 Mar. Cureus. 2025. PMID: 40190902 Free PMC article.
-
Uterine sarcoma: a clinical case and a literature review.Acta Med Litu. 2018;25(4):206-218. doi: 10.6001/actamedica.v25i4.3931. Acta Med Litu. 2018. PMID: 31308826 Free PMC article.
References
-
- Naaman Y, Shveiky D, Ben-Shachar I, Shushan A, Mejia-Gomez J, Benshushan A. Uterine sarcoma: prognostic factors and treatment evaluation. IMAJ. 2011;13:76–79. - PubMed
-
- Nassar OA, Abdul Moaty SB, Khalil e-SA, El-Taher MM, El Najjar M. Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results. J Egypt Natl Canc Inst. 2010;22(2):113–122. - PubMed
-
- Prat J (2009) FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 104(3):177–178 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources